BACKGROUND: We investigated the differences in clinical presentation of patients with hepatocellular carcinoma (HCC) at the time of diagnosis, before and after the publication of the European Association for the study of the Liver (EASL) guidelines of HCC management and screening. METHODS: Between 1991 and 2009, 907 patients were diagnosed with HCC at our department of which 850 were included in this study. Data regarding demography, liver function and tumor stage at the time of diagnosis were retrospectively collected. Differences in clinical characteristics and overall survival (OS) were compared before (period 1) and after (period 2) the publication of the EASL guidelines in 2001. RESULTS: In period 2, patients were more likely to be overweight (BMI: 26.1 vs. 27.5, p = 0.003), suffered more often from diabetes (25.4 vs. 37.3%, p = 0.001) and nonalcoholic steatohepatitis (NASH) (0.7 vs. 5.1%, p < 0.001). Alcoholic liver disease replaced viral hepatitis as the main etiology but not in the increasing number of patients with migration background where viral hepatitis (76.3%) remained the predominant etiology. No change in liver function and tumor stages at the time of HCC diagnosis was observed. Most patients presented with advanced incurable HCC. However, the median OS of all HCC patients increased in period 2 (7 vs. 14 months, p < 0.001) suggesting improvements of palliative therapy. CONCLUSIONS: Patients with HCC are still predominantly diagnosed at incurable tumor stages, despite explicit European screening guidelines existing since 9 years. The implementation of a HCC surveillance program for cirrhotic patients in Austria seems to be warranted.
BACKGROUND: We investigated the differences in clinical presentation of patients with hepatocellular carcinoma (HCC) at the time of diagnosis, before and after the publication of the European Association for the study of the Liver (EASL) guidelines of HCC management and screening. METHODS: Between 1991 and 2009, 907 patients were diagnosed with HCC at our department of which 850 were included in this study. Data regarding demography, liver function and tumor stage at the time of diagnosis were retrospectively collected. Differences in clinical characteristics and overall survival (OS) were compared before (period 1) and after (period 2) the publication of the EASL guidelines in 2001. RESULTS: In period 2, patients were more likely to be overweight (BMI: 26.1 vs. 27.5, p = 0.003), suffered more often from diabetes (25.4 vs. 37.3%, p = 0.001) and nonalcoholic steatohepatitis (NASH) (0.7 vs. 5.1%, p < 0.001). Alcoholic liver disease replaced viral hepatitis as the main etiology but not in the increasing number of patients with migration background where viral hepatitis (76.3%) remained the predominant etiology. No change in liver function and tumor stages at the time of HCC diagnosis was observed. Most patients presented with advanced incurable HCC. However, the median OS of all HCC patients increased in period 2 (7 vs. 14 months, p < 0.001) suggesting improvements of palliative therapy. CONCLUSIONS:Patients with HCC are still predominantly diagnosed at incurable tumor stages, despite explicit European screening guidelines existing since 9 years. The implementation of a HCC surveillance program for cirrhotic patients in Austria seems to be warranted.
Authors: Albert C Y Chan; Ronnie T P Poon; Kelvin K C Ng; Chung Mau Lo; Sheung Tat Fan; John Wong Journal: Ann Surg Date: 2008-04 Impact factor: 12.969
Authors: Mary Y Y Qian; Rong Yuwei J; Peter Angus; Tony Schelleman; Lynne Johnson; Paul Gow Journal: J Gastroenterol Hepatol Date: 2010-05 Impact factor: 4.029
Authors: M Schöniger-Hekele; C Müller; M Kutilek; C Oesterreicher; P Ferenci; A Gangl Journal: Eur J Gastroenterol Hepatol Date: 2000-08 Impact factor: 2.566
Authors: Markus Peck-Radosavljevic; Paolo Angeli; Juan Cordoba; Oliver Farges; Dominique Valla Journal: United European Gastroenterol J Date: 2015-02 Impact factor: 4.623
Authors: Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh Journal: Br J Radiol Date: 2018-08-29 Impact factor: 3.039
Authors: Ramanathan M Seshadri; Siddesh Besur; David J Niemeyer; Megan Templin; Iain H McKillop; Ryan Z Swan; John B Martinie; Mark W Russo; David A Iannitti Journal: HPB (Oxford) Date: 2014-06-25 Impact factor: 3.647
Authors: Matthias Pinter; Wolfgang Sieghart; Monika Schmid; Bernhard Dauser; Gerald Prager; Hans Peter Dienes; Michael Trauner; Markus Peck-Radosavljevic Journal: United European Gastroenterol J Date: 2013-08 Impact factor: 4.623
Authors: Bernhard Scheiner; Martha Kirstein; Sabine Popp; Florian Hucke; Simona Bota; Nataliya Rohr-Udilova; Thomas Reiberger; Christian Müller; Michael Trauner; Markus Peck-Radosavljevic; Arndt Vogel; Wolfgang Sieghart; Matthias Pinter Journal: Liver Cancer Date: 2018-06-22 Impact factor: 11.740
Authors: Matthias Pinter; Arndt Weinmann; Marcus-Alexander Wörns; Florian Hucke; Simona Bota; Jens U Marquardt; Dan G Duda; Rakesh K Jain; Peter R Galle; Michael Trauner; Markus Peck-Radosavljevic; Wolfgang Sieghart Journal: United European Gastroenterol J Date: 2017-02-26 Impact factor: 4.623